ReNerve Lands Malaysian Partner to Sell Nerve Repair Products to 33M People
ReNerve secures Malaysian distribution partner for NervAlign nerve repair range
ReNerve Limited has executed a distribution agreement with UG Medical for the Malaysian market, marking a commercialisation milestone for its NervAlign nerve repair product range. The partnership leverages regulatory clearance already secured through Malaysia’s Medical Device Authority (MDA) earlier this year, positioning the company to enter a market of approximately 33 million people in one of Southeast Asia’s fastest-growing healthcare sectors.
When big ASX news breaks, our subscribers know first
What the UG Medical partnership delivers
Under the agreement, Kuala Lumpur-based UG Medical will handle importation, regulatory management, warehousing, and collaborate with ReNerve on marketing, sales, and distribution of the NervAlign product range across Malaysia. The company brings an established network spanning Malaysian hospitals and healthcare facilities, providing immediate market access for ReNerve’s nerve repair technologies.
Malaysian regulatory approval through the Medical Device Authority established the commercial foundation the UG Medical partnership now builds on, with the clearance positioning NervAlign as one of only a handful of bioabsorbable nerve repair products formally registered in the Southeast Asian market.
ReNerve’s obligations under the open-ended agreement include ongoing clinical and technical support, product training, and regulatory liaison to support commercialisation activities. The arrangement operates on customary commercial terms standard for medical device distribution partnerships.
Partnership structure:
- UG Medical responsibilities: Importation, regulatory management, warehousing, marketing/sales/distribution
- ReNerve responsibilities: Clinical support, product training, regulatory liaison
Understanding peripheral nerve repair and the NervAlign range
Peripheral nerve injury (PNI) occurs when nerves outside the brain and spinal cord are damaged through trauma, surgery, or disease. Surgical repair remains challenging because reconnected nerves require protection during the healing process, which can take months. Without adequate protection, scar tissue formation and inflammation can prevent proper nerve regeneration.
The NervAlign Nerve Cuff addresses this clinical challenge by creating a protective environment around repaired nerves. The bioabsorbable wrap naturally dissolves within six months of surgery, eliminating the need for removal procedures. ReNerve’s nerve conduit product, which ReNerve is looking to launch in Malaysia later this year, targets nerve gaps where severed nerve ends cannot be directly joined.
The global nerve repair biomaterials market was valued at US$1.6 billion in 2024, with projections indicating growth to US$6.2 billion by 2031. This expansion reflects increasing recognition of peripheral nerve injuries as a significant healthcare burden requiring specialised surgical solutions.
Why Malaysia represents a strategic market
Malaysia’s well-developed public hospital network and expanding private healthcare sector create favourable conditions for medical device adoption. The Malaysian government has committed to ongoing healthcare infrastructure investment under its 12th Malaysia Plan framework, with particular emphasis on surgical capability and specialist services.
ReNerve’s Asia sales and marketing team has already established relationships with hospitals across the region, providing groundwork for commercial launch. The company will serve as a major sponsor for a hand surgery teaching event in Kuala Lumpur in June 2026, demonstrating its clinical engagement strategy in the market.
The distribution partnership leverages existing regulatory approval, removing a significant commercialisation barrier. Malaysia’s government investment in surgical infrastructure creates adoption tailwinds for innovative medical technologies addressing unmet clinical needs.
CEO perspective on regional expansion
Dr Julian Chick, CEO, ReNerve
“This agreement with UG Medical represents a compelling opportunity to establish NervAlign in the Malaysian market, which is one of Southeast Asia’s most progressive and well-developed healthcare systems. UG Medical’s relationships and in-market expertise make them an outstanding partner for ReNerve as we continue to build our commercial presence across the Asia-Pacific region.”
“NervAlign addresses a significant and underserved clinical need in peripheral nerve repair and Malaysia’s growing investment in surgical infrastructure and specialist care creates a strong environment for adoption. We look forward to working with the UG Medical team to bring NervAlign to surgeons and patients across Malaysia.”
The next major ASX story will hit our subscribers first
ReNerve’s commercial momentum and next steps
The Malaysian partnership builds on ReNerve’s broader growth trajectory. The company achieved 53% revenue growth in FY25, reaching $271,000 in sales. The nerve conduit product launch in Malaysia later this year will expand the available product range, providing surgeons with solutions for both direct nerve repairs and cases requiring bridging of nerve gaps.
That trajectory accelerated sharply into the following fiscal year, with ReNerve posting 79% quarter-on-quarter revenue growth in Q3 FY26 and recording its first-ever $100,000 sales month in March 2026, supported by an expanded US distributor network of 21 active partners.
| Element | Status |
|---|---|
| NervAlign Nerve Cuff | MDA approved |
| NervAlign Nerve Conduit | Launch expected later 2026 |
| Distribution partner | UG Medical (agreement executed) |
| Regional support | Asia sales team in place |
The Malaysian market entry forms part of ReNerve’s Asia-Pacific commercial expansion strategy, with the distribution partnership providing a foundation for establishing NervAlign products across the region’s surgical community.
Want the Next MedTech Winner in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements the moment they drop.